SIGA

SIGA Technologies Inc. - 10-Q Summary (Q1 2005)

Business Context and Reporting Period

This Form 10-Q covers the three-month period ended March 31, 2005. SIGA Technologies, Inc. is a biotechnology company focused on the research and development of novel products for infectious diseases, including biological warfare agents (Smallpox, Arenaviruses) and drug-resistant bacteria. The company has no commercial products and relies on government grants (NIH SBIR) and contracts (U.S. Army) for revenue. Management believes current cash flows are sufficient to support operations beyond March 31, 2006, though continued financing is required.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Surge: Revenues increased 805% to $1.46 million, driven primarily by the recognition of revenue from two Phase I and two Phase II NIH SBIR grants awarded in late 2004 (totaling approx. $12.1 million). NIH grants accounted for 94% of Q1 2005 revenue compared to 45% in Q1 2004.
• Improved Net Loss: Net loss decreased by 43% to $1.11 million, despite higher operating expenses, due to the significant revenue increase.
• Expense Increases: Research and development (R&D) expenses rose 52% to $1.55 million, largely due to preclinical development work and increased amortization of intangible assets ($274k vs $96k). Patent preparation fees increased 90% to $175k following asset acquisitions.
• Expense Decreases: Selling, general, and administrative (SG&A) expenses declined 16% to $845k, attributed to reduced legal, accounting, and consulting fees, partially offset by higher payroll costs for new executive hires.
• Cash Position: Cash and cash equivalents decreased by $989,837 during the quarter, primarily due to operating cash burn and significant capital expenditures ($363k) for laboratory equipment and facilities.

Outlook, Risks, and Management Commentary

• Liquidity: Management projects sufficient cash to fund operations through March 31, 2006. However, the company has no commercial products and expects to incur losses for the foreseeable future.
• Financing Needs: Future development depends on obtaining additional federal grants, contracts, or private financing. There is no assurance that such funding will be available on acceptable terms.
• Development Risks: All product programs are in early stages. There is a high risk of non-completion due to the long lead times and uncertainty of costs. Products for biological warfare defense may be available in 1-3 years if development proceeds as scheduled.
• Accounting Changes: The company is assessing the impact of SFAS 123R (Share-Based Payment), which will require the recognition of non-cash stock-based compensation expenses starting in 2006, potentially increasing reported losses.
• Going Concern: The financial statements are prepared assuming the company will continue as a going concern, contingent upon successful R&D and adequate financing.

Investor Verification Checklist

• Grant Sustainability: Verify the status and renewal likelihood of the NIH SBIR grants and U.S. Army contracts that currently drive 94% of revenue.
• Cash Runway: Confirm the accuracy of the projection that cash reserves will last beyond March 31, 2006, given the current burn rate of approx. $1M per quarter.
• Capital Expenditures: Review the necessity and ROI of the $363k in capital expenditures incurred in Q1 2005.
• Stock-Based Compensation: Monitor the impact of the upcoming adoption of SFAS 123R on future net loss figures.
• Related Party Transactions: Review the service agreement with TransTech Pharma (Exhibit 10.1) and the Master Security Agreement with GE Capital (Exhibit 10.2) filed in May 2005.